Skip to main
IMRX

Immuneering Corp (IMRX) Stock Forecast & Price Target

Immuneering Corp (IMRX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immuneering Corp has demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) rates when compared to the standard of care (SoC), indicating the potential effectiveness of its therapeutics. The safety profile of Immuneering’s lead candidate, atebimetinib, shows favorable tolerability over existing therapies, which may enhance patient adherence and outcomes. Additionally, preliminary case studies highlight remarkable patient responses, suggesting the potential for innovative treatment pathways in difficult-to-treat conditions such as pancreatic cancer, further strengthening the company's outlook in the biopharmaceutical market.

Bears say

The analysis highlights several fundamental concerns regarding Immuneering Corp's stock outlook, primarily stemming from regulatory risks associated with its products. Even if clinical trials meet their endpoints, the possibility of failing to secure regulatory approval poses a significant threat to the company's financial projections, potentially leading to downward revisions. Additionally, the need for further capital-raising measures to achieve profitability may result in share dilution, compounding the existing financial risks for investors.

Immuneering Corp (IMRX) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immuneering Corp (IMRX) Forecast

Analysts have given Immuneering Corp (IMRX) a Buy based on their latest research and market trends.

According to 6 analysts, Immuneering Corp (IMRX) has a Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immuneering Corp (IMRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.